TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11857663

Group type: EXPERIMENTAL
Intervention: Transurethral incision of the prostate (TUIP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 100
Study: 8000836

Group type: EXPERIMENTAL
Intervention: Iotrolan (iso-osmolar non-ionic contrast medium)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iohexol (conventional non-ionic contrast medium) with adrenaline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iohexol (conventional non-ionic contrast medium) without adrenaline
Number of subjects: 0
Study: 2905150

Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ebastine 50 mg
Number of subjects: 0
Study: 29946832

Group type: EXPERIMENTAL
Intervention: Screw-retained monolithic zirconia crowns
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cemented porcelain-fused-to-metal crowns
Number of subjects: 22
Study: 28925703

Group type: EXPERIMENTAL
Intervention: Cyclic tetramer of zirconium hydroxide [Zr4(OH)16]
Number of subjects: 0
Study: 25872563

Group type: EXPERIMENTAL
Intervention: Sustained inflation (SI) with PEEP (initial SI at 20 cm H2O for 15 seconds followed by a second SI at 25 cm H2O for 15 seconds)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Intermittent positive pressure ventilation (IPPV) with PEEP
Number of subjects: 600
Study: 23758662

Group type: EXPERIMENTAL
Intervention: Centralised laboratory positioning of Xpert MTB/RIF system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Primary health care clinic positioning of Xpert MTB/RIF system
Number of subjects: 0
Study: 21647578

Group type: EXPERIMENTAL
Intervention: Org 26576 (0.1-10 mg/kg, i.v.)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Org 26576 (100 mg QD)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Org 26576 (400 mg BID)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: EC(80) target concentration
Number of subjects: 41
Study: 19318455

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen (TD E2)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conjugated oral estrogen
Number of subjects: 12
Study: 16892908

Group type: EXPERIMENTAL
Intervention: Zero-inflated Negative Binomial (ZINB) model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative Binomial Hurdle (NBH) model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Poisson model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative Binomial (NB) model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zero-inflated Poisson (ZIP) model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Poisson Hurdle (PH) model
Number of subjects: 0
Study: 15605118

Group type: EXPERIMENTAL
Intervention: Quetiapine (monotherapy or combined with mood stabilizers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 0
Study: 11599198

Group type: EXPERIMENTAL
Intervention: Spironolactone (average starting dosage 55 mg)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Spironolactone with ACE-inhibitor
Number of subjects: 243

Group type: COMPARATOR
Intervention: ACE-inhibitor
Number of subjects: 243

Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 243

Group type: COMPARATOR
Intervention: Spironolactone and ACE-inhibitor
Number of subjects: 243
Study: 9394235

Group type: EXPERIMENTAL
Intervention: Faropenem (FRPM) only (S-group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Faropenem (FRPM) in combination with Enteronon-R (E-group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Faropenem (FRPM)
Number of subjects: 40
Study: 8424507

Group type: EXPERIMENTAL
Intervention: Epidural morphine (EM) 100 micrograms/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidural morphine (EM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous morphine (IM)
Number of subjects: 0
Study: 3263098

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 5072238

Group type: EXPERIMENTAL
Intervention: +/- propranolol (120 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: +/- sotalol (240 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both sotalol and propranolol
Number of subjects: 0
Study: 31100124

Group type: EXPERIMENTAL
Intervention: Probiotic mixture (Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium bifidum, and Bifidobacterium lactis)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Probiotic mixture
Number of subjects: 181
Study: 31712617

Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 3 months
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control intervention (table soccer) for 3 months
Number of subjects: 43
Study: 28111006

Group type: EXPERIMENTAL
Intervention: Early motion protocol (starting 2 to 3 days after surgery)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Delayed motion protocol (starting 28 days after surgery)
Number of subjects: 73
Study: 25907815

Group type: EXPERIMENTAL
Intervention: Rapid naltrexone induction with buprenorphine-clonidine procedure
Number of subjects: 150
Study: 22956408

Group type: EXPERIMENTAL
Intervention: anti-D immunoglobulin (50 μg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: methylprednisolone (2 mg/kg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: intravenous immunoglobulin (IVIG, 0.4 g/kg/day for 5 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: IVIG
Number of subjects: 60
Study: 22003869

Group type: EXPERIMENTAL
Intervention: Artesunate (AS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CYP2A6 genotyping
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Gender (female)
Number of subjects: 24
Study: 18704101

Group type: EXPERIMENTAL
Intervention: Active TMS (transcranial magnetic stimulation) administered to the left dorsolateral prefrontal cortex at 10 pulses per second, 120% of motor threshold, for a total of 3000 pulses per day
Number of subjects: 301

Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 301
Study: 17311688

Group type: EXPERIMENTAL
Intervention: Gemcitabine followed by Docetaxel
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Docetaxel followed by Gemcitabine
Number of subjects: 330
Study: 15295352

Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX) 60 mg/day
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Slow-dose escalation (SDE)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 487
Study: 11330366

Group type: EXPERIMENTAL
Intervention: Regional antimicrobial prophylaxis (teicoplanin 400 mg)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Perioperative antibiotic prophylaxis (teicoplanin 800 mg)
Number of subjects: 217
Study: 9509504

Group type: EXPERIMENTAL
Intervention: rHuEPO (300 IU/kg, subcutaneously, three times a week for 6‐8 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no rHuEPO)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: rHuEPO
Number of subjects: 34
Study: 8312032

Group type: EXPERIMENTAL
Intervention: Graphical feedback
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tabular feedback
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Graphical feedback plus facilitator visit
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Manual audit of risk factors
Number of subjects: 52

Group type: COMPARATOR
Intervention: All feedback types
Number of subjects: 52
Study: 3049484

Group type: EXPERIMENTAL
Intervention: Standard hospital discharge feeding gift pack containing formula
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Specially designed study pack that was free of infant formula
Number of subjects: 60
Study: 30813701

Group type: EXPERIMENTAL
Intervention: Nasal endoscope combined with supporting laryngoscope surgery
Number of subjects: 94

Group type: COMPARATOR
Intervention: Simply supporting laryngoscope surgery
Number of subjects: 94
Study: 28040281

Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention Program (LIP)
Number of subjects: 173
Study: 26622463

Group type: EXPERIMENTAL
Intervention: 5% 5-ALA for 1.5 h followed by three 20-min doses of infrared radiation once a week for 3 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Three 20-min doses of infrared radiation without 5-ALA once a week for 3 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 5% 5-ALA PDT
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group treatment
Number of subjects: 50
Study: 23463180

Group type: EXPERIMENTAL
Intervention: Telephone-assisted parent-administered behavioural intervention (bibliotherapy) with 11 chapter self-help book and 11 weekly telephone consultations
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Telephone-assisted parent-administered behavioural intervention (bibliotherapy)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Untreated waitlist control group
Number of subjects: 48
Study: 21410369

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 419

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419
Study: 18000162

Group type: EXPERIMENTAL
Intervention: Atorvastatin (n = 19)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No treatment (n = 26)
Number of subjects: 45
Study: 15882894

Group type: EXPERIMENTAL
Intervention: DX-9065a (1 of 4 weight-adjusted regimens)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 14656777

Group type: EXPERIMENTAL
Intervention: Rofecoxib (ROF) 50 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 20
Study: 12545843

Group type: EXPERIMENTAL
Intervention: IFN alpha‐2a 3MIU i.m. once a week for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prednisone 1 mg/(kg.d) for 4 weeks
Number of subjects: 20
Study: 8873580

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT2) 24 mg daily
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Spirapril 6 mg daily
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 1526086

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 12
Study: 2859256

Group type: EXPERIMENTAL
Intervention: Alprazolam (1.2 mg/day)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Gefarnate (300 mg/day)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Combination of alprazolam and gefarnate
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 139
Study: 30807279

Group type: EXPERIMENTAL
Intervention: .065 g/dl alcohol dose
Number of subjects: 180

Group type: COMPARATOR
Intervention: .00 g/dl alcohol dose
Number of subjects: 180

Group type: COMPARATOR
Intervention: .04 g/dl alcohol dose
Number of subjects: 180
Study: 29301367

Group type: EXPERIMENTAL
Intervention: CHO ingestion at 40 g·h‐1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CHO ingestion at 39 g·h‐1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CHO ingestion at 20 g·h‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: CHO ingestion at 0 g·h‐1 (control - water)
Number of subjects: 20
Study: 26924381

Group type: EXPERIMENTAL
Intervention: Isokinetic muscle exercising associated with aerobic exercising
Number of subjects: 40

Group type: COMPARATOR
Intervention: Only aerobic exercising
Number of subjects: 40
Study: 24530167

Group type: EXPERIMENTAL
Intervention: PtCr‐EES (PROMUS Element platinum‐chromium everolimus‐eluting stent)
Number of subjects: 1530

Group type: COMPARATOR
Intervention: CoCr‐EES (XIENCE V cobalt‐chromium everolimus‐eluting stent)
Number of subjects: 1530

Group type: EXPERIMENTAL
Intervention: PtCr‐EES
Number of subjects: 1530

Group type: COMPARATOR
Intervention: CoCr‐EES
Number of subjects: 1530
Study: 22387150

Group type: EXPERIMENTAL
Intervention: Web-based self-management intervention for BD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 20536790

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cyclosporin A (CsA)
Number of subjects: 29
Study: 17299612

Group type: EXPERIMENTAL
Intervention: Induction therapy with interferon‐alpha (IFN‐alpha)‐2b (three million units, daily for eight weeks followed by three million units, three times a week for a further 16 to 40 weeks) and daily ribavirin (1.0 g to 1.2 g according to weight for 24 to 48 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard IFN‐alpha2b therapy (three million units, three times weekly for 24 to 48 weeks) and daily ribavirin (1.0 g to 1.2 g according to weight for 24 to 48 weeks)
Number of subjects: 54
Study: 15292792

Group type: EXPERIMENTAL
Intervention: HA-coated lag and cortical AO/ASIF screws (Group B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard lag and cortical AO/ASIF screws (Group A)
Number of subjects: 120
Study: 11142669

Group type: EXPERIMENTAL
Intervention: Braun Oral‐B Plak Control Ultra electric toothbrush
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Braun Oral‐B Plak Control 3D electric toothbrush
Number of subjects: 26

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 26
Study: 9426022

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) 0.5 microg/kg body weight per min
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg three times daily with NTG
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg three times daily without NTG
Number of subjects: 40
Study: 8608428

Group type: EXPERIMENTAL
Intervention: Naturalistic prospective follow-up study over 2 years
Number of subjects: 40
Study: 2469711

Group type: EXPERIMENTAL
Intervention: Alpha interferons or adenine arabinoside 5'-monophosphate treatment
Number of subjects: 66

Group type: COMPARATOR
Intervention: No therapy (untreated controls)
Number of subjects: 66

Group type: COMPARATOR
Intervention: No therapy (non-responders)
Number of subjects: 66
Study: 19507

Group type: EXPERIMENTAL
Intervention: Win 20,836 (8-methoxycyclazocine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 0
Study: 29985079

Group type: EXPERIMENTAL
Intervention: One-step approach (75-g glucose load, fasting, 1h, and 2h measurements)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Two-step approach (50-g glucose load followed by 100-g glucose load if necessary)
Number of subjects: 249
Study: 30046942

Group type: EXPERIMENTAL
Intervention: Barley kernel bread (BKB)
Number of subjects: 99

Group type: COMPARATOR
Intervention: White wheat bread (control)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: High Prevotella/Bacteroides (HP)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: High abundance of both (HPB)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Low Prevotella/Bacteroides (LP)
Number of subjects: 99
Study: 28028994

Group type: EXPERIMENTAL
Intervention: Genexol-PM (300 mg/m², once every 3 weeks) + carboplatin (AUC 5)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Genexol-PM (220 mg/m², once every 3 weeks) + carboplatin (AUC 5)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Genexol-PM (260 mg/m², once every 3 weeks) + carboplatin (AUC 5)
Number of subjects: 18
Study: 26352813

Group type: EXPERIMENTAL
Intervention: Sebelipase alfa (1 mg/kg, intravenously, every other week)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Sebelipase alfa
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sebelipase alfa and Placebo
Number of subjects: 66
Study: 23345000

Group type: EXPERIMENTAL
Intervention: Oral CP-4126 (100-3000 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Oral CP-4126
Number of subjects: 26
Study: 21836088

Group type: EXPERIMENTAL
Intervention: Baseline diastolic blood pressure (DBP)
Number of subjects: 1281

Group type: COMPARATOR
Intervention: Increase in DBP >5 mm Hg from baseline to MRI
Number of subjects: 1281
Study: 19882058

Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg plus 25 ug of fentanyl
Number of subjects: 61

Group type: COMPARATOR
Intervention: Bupivacaine 5 mg plus 25 ug of fentanyl
Number of subjects: 61
Study: 16758644

Group type: EXPERIMENTAL
Intervention: Intracoronary injection of bone marrow mononuclear cells
Number of subjects: 44
Study: 12033348

Group type: EXPERIMENTAL
Intervention: Lead configuration (dual-coil transvenous defibrillation lead)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Active can configuration (active pectoral electrode)
Number of subjects: 33
Study: 10422902

Group type: EXPERIMENTAL
Intervention: Reinforced antenatal clinic routines including hematinic and malaria prophylaxis, retraining of staff, group and individual counselling, and community health education.
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Standard antenatal care without the additional interventions.
Number of subjects: 1045
Study: 7587254

Group type: EXPERIMENTAL
Intervention: Interleukin-2 treatment
Number of subjects: 0
Study: 2144796

Group type: EXPERIMENTAL
Intervention: Quinidine therapy
Number of subjects: 808

Group type: COMPARATOR
Intervention: Control group (no antiarrhythmic therapy)
Number of subjects: 808
Study: 7001961

Group type: EXPERIMENTAL
Intervention: Flunisolide (inhaled steroid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31715161

Group type: EXPERIMENTAL
Intervention: Broad-spectrum combination empiric antibiotics
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Confirmed sepsis at admission
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Trauma patients
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Clostridium difficile enteritis
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 29
Study: 29506014

Group type: EXPERIMENTAL
Intervention: Milking Maneuver (MM)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Early cord clamping
Number of subjects: 138
Study: 27720404

Group type: EXPERIMENTAL
Intervention: Surgical Video Coaching (SVC) group, n = 14
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group, n = 14
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SVC group satisfaction survey
Number of subjects: 28
Study: 25939614

Group type: EXPERIMENTAL
Intervention: Antipsychotic augmentation (quetiapine, risperidone, aripiprazole, olanzapine, paliperidone, haloperidol)
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 491

Group type: COMPARATOR
Intervention: Antipsychotics
Number of subjects: 491

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 491
Study: 23124798

Group type: EXPERIMENTAL
Intervention: Postpartum depressive symptoms measured by the Edinburgh Postnatal Depression Scale (EPDS) at 4-15 weeks postpartum, with a score ≥9 indicating depressive symptoms.
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Cesarean delivery
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Gestational weight gain
Number of subjects: 71
Study: 21044166

Group type: EXPERIMENTAL
Intervention: Implant-cantilever group (1 implant with cantilever)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Implant-implant group (2 adjacent implants)
Number of subjects: 10
Study: 19739431

Group type: EXPERIMENTAL
Intervention: Ciclesonide hydrofluoroalkane nasal aerosol 300 microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciclesonide hydrofluoroalkane nasal aerosol 150 microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciclesonide hydrofluoroalkane nasal aerosol 75 microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciclesonide hydrofluoroalkane nasal aerosol (all doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17531578

Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg/day for 3 to 6 weeks before and 16 mg/day for 6 months after electrical cardioversion
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 15768732

Group type: EXPERIMENTAL
Intervention: Probiotics (1.2g/d) and soluble fiber (11g/d) with L-Glutamine (30g/d) if diarrhea persisted at week 4
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 35
Study: 11328258

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg
Number of subjects: 36
Study: 9740159

Group type: EXPERIMENTAL
Intervention: Manual biopsy using a 14 G Tru-cut needle (group 1, 67 patients)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Automated biopsy using an 18 G gun (group 2, 99 patients)
Number of subjects: 166
Study: 8046601

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) monotherapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison estimates assuming a constant concentration/dose ratio
Number of subjects: 22
Study: 2737271

Group type: EXPERIMENTAL
Intervention: Formoterol (12 micrograms twice daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Salbutamol (200 micrograms twice daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 20
Study: 31833144

Group type: EXPERIMENTAL
Intervention: Abused women
Number of subjects: 2621

Group type: COMPARATOR
Intervention: Non-abused women
Number of subjects: 2621
Study: 29278659

Group type: EXPERIMENTAL
Intervention: Lower levels of serum exosomal miR-638
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Over-expression of miR-638 in Huh7 and SMCC7721 HCC cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum exosomal miR-638 levels
Number of subjects: 0
Study: 27939076

Group type: EXPERIMENTAL
Intervention: Simtuzumab (125 mg/mL, subcutaneously once a week)
Number of subjects: 544

Group type: COMPARATOR
Intervention: Placebo (subcutaneously once a week)
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Simtuzumab and Placebo
Number of subjects: 544
Study: 26700866

Group type: EXPERIMENTAL
Intervention: Modified unconditional cash transfer (21,500 FCFA/month for 5 months, 22,500 FCFA in June)
Number of subjects: 3500

Group type: COMPARATOR
Intervention: Standard unconditional cash transfer (32,500 FCFA/month for 4 months)
Number of subjects: 3500